Due to tumor cell dependence on B-cell receptor signaling and NF-κB signaling, the inhibition of the Bruton tyrosine kinase by ibrutinib achieves high efficacy in relapsed/refractory MCL [6]. The gene discussed is BTK; the disease is mantle cell lymphoma.